News stories about KalVista Pharmaceuticals (NASDAQ:KALV) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. KalVista Pharmaceuticals earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 47.7466946543436 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- KalVista Pharmaceuticals (KALV) and Cardiome Pharma Corporation (CRME) Financial Survey (americanbankingnews.com)
- KalVista Pharmaceuticals, Inc. :KALV-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017 (finance.yahoo.com)
- Insider Selling: KalVista Pharmaceuticals, Inc. (KALV) Major Shareholder Sells 176,647 Shares of Stock (americanbankingnews.com)
- Holdings A/S Novo Sells 10,000 Shares of KalVista Pharmaceuticals, Inc. (KALV) Stock (americanbankingnews.com)
- KalVista Pharmaceuticals, Inc. (KALV) Major Shareholder Holdings A/S Novo Sells 25,900 Shares (americanbankingnews.com)
KALV has been the subject of a number of recent analyst reports. ValuEngine raised shares of KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 2nd. BTIG Research initiated coverage on shares of KalVista Pharmaceuticals in a report on Thursday, August 31st. They issued a “buy” rating and a $18.00 price objective for the company.
KalVista Pharmaceuticals (NASDAQ KALV) traded up 1.271% on Tuesday, reaching $6.775. 2,458 shares of the company’s stock were exchanged. The company’s market capitalization is $65.81 million. The firm has a 50-day moving average price of $7.95 and a 200-day moving average price of $7.87. KalVista Pharmaceuticals has a 1-year low of $6.09 and a 1-year high of $10.65.
KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, September 14th. The specialty pharmaceutical company reported ($0.51) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.08. KalVista Pharmaceuticals had a negative net margin of 4,191.47% and a negative return on equity of 60.42%. The company had revenue of $0.10 million during the quarter. Equities research analysts expect that KalVista Pharmaceuticals will post ($2.94) earnings per share for the current year.
In other news, major shareholder Holdings A/S Novo sold 10,000 shares of the firm’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $8.05, for a total value of $80,500.00. Following the completion of the sale, the insider now owns 2,876,027 shares in the company, valued at approximately $23,152,017.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 212,547 shares of company stock valued at $1,561,843 in the last 90 days. Company insiders own 49.10% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “KalVista Pharmaceuticals (KALV) Receiving Somewhat Positive Press Coverage, Analysis Finds” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/2903541/kalvista-pharmaceuticals-kalv-receiving-somewhat-positive-press-coverage-analysis-finds.html.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.